Abstract 105P
Background
PD-1 blockade has brought impressive response rate in pts with dMMR/MSI-H solid tumors compared with chemotherapy. QL1604, a novel anti-PD-1 antibody, has shown good safety and preliminary anti-tumor activity in advanced solid tumors in the phase I study.
Methods
This single-arm, phase II study (NCT04326829) evaluated the efficacy and safety of QL1604 in pts with unresectable or metastatic dMMR/MSI-H solid tumors from 38 clinical sites across China. Pts received QL1604 (200 mg, iv, Q3W; 3 mg/kg for pts with body weight <40 kg, Q3W), until disease progression, intolerance, withdrawal of consent, or up to 2 years (whichever occurred first). The primary endpoint was objective response rate (ORR) assessed by independent radiological review committee (IRRC) per RECIST 1.1.
Results
From Jun 19, 2020 to Jan 12, 2023, 120 pts with dMMR/MSI-H solid tumors were enrolled, of whom 80 (66.7%) pts had colorectal cancer (CRC), 18 (15.0%) pts had gastric cancer, and 22 (18.3%) had other solid tumors. A total of 97.5% pts had stage IV disease at study entry, and the median prior therapy lines was 2.0 (range, 0-6). With median follow-up of 13.59 mo (range, 0.5–35.3 mo), the ORR and DCR per IRRC were 55/120 (45.8%; 95% CI: 36.7%–55.2%) and 93/120 (77.5%, 95% CI: 69.0%–84.6%), respectively, with 11 (9.2%) complete response (CR) and 44 (36.7%) partial response. In the CRC subgroup, the ORR and DCR per IRRC were 34/80 (42.5%, 95% CI: 31.5%–54.1%) and 62/80 (77.5%, 95% CI: 66.8%–86.1%), respectively. Overall, median duration of response (DoR) was not reached, with 6-mo and 12-mo DoR rates of 100% (95% CI: NE–NE) and 97.4% (95% CI: 83.2%–99.6%), respectively. Median progression-free survival and median overall survival were not reached. TEAEs of any grade occurred in 117 (97.5%) pts. The most frequent treatment-related adverse events (TRAEs) of any grade and grade ≥3 TRAEs were both anemia, with incidence of 25.8% and 5.0%, respectively. No QL1604-related death occurred.
Conclusions
QL1604 showed promising efficacy with high response rate and durable response and tolerable toxicity in pts with dMMR/MSI-H solid tumors.
Clinical trial identification
NCT04326829.
Editorial acknowledgement
Legal entity responsible for the study
Qilu Pharmaceutical Co., Ltd.
Funding
Qilu Pharmaceutical Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract